Represent pharmaceutical, medical device, diagnostic, and medical supply companies, as well as other healthcare institutions, in various healthcare fraud investigations conducted by federal and state enforcement agencies involving billing and pricing issues, allegations of improper sales and marketing practices, allegations of off-label promotion, and alleged violations of the False Claims Act and the Anti-Kickback Statute.
Represent major airline in ongoing federal criminal and civil investigations in connection with federal contract issues.
Represent diagnostics company in qui tam litigation pending in Massachusetts regarding alleged improper billing practices.
Represent diagnostics company in qui tam litigation under the California Insurance Frauds Prevention Act regarding alleged improper billing practices.
Represent pharmaceutical company in qui tam litigation pending in Pennsylvania regarding the alleged off-label promotion of a prescription drug and other alleged improper sales and marketing practices.
Represent medical device manufacturer in qui tam litigation pending in Massachusetts regarding the alleged improper off-label promotion of medical devices and other alleged improper sales and marketing practices. Achieved successful dismissal of False Claims Act claims and only employment-related claims remain pending.
Represented medical device manufacture in qui tam litigation in Texas regarding the alleged off-label promotion of a medical device. Following three week trial in which over $1 billion in damages was sought, the jury returned a complete defense verdict after three hours of deliberation.
Represented pharmaceutical company in qui tam litigation pending in Ohio regarding the alleged off-label and improper promotion of several prescription drugs and other alleged improper sales and marketing practices.
Represented pharmaceutical manufacturers in various actions brought in state and federal courts on behalf of state Medicaid agencies and the federal government asserting that prescription pharmaceutical manufacturers reported inaccurate pricing benchmarks, allegedly causing the states and federal government to overpay providers for drugs dispensed to Medicaid and Medicare beneficiaries.
